Interview with Iryna Gorlova, General Director, Support in Market Development…
As the founder of SMD what was it the prompted you to create this company and what were your objectives at that time? Up until 2003 when I created SMD,…
Address: Bojenko str., 86i, Kiev 03680, Ukraine
Tel: +38 044 206 17 17
SUPPORT
Our analytical, commercial services and consulting capabilities are key to achieving high-quality, cost-effective support in the following areas:
Regular market services (Customs Import Report, Retail and Hospital Consumption Report, Distributors’ Report, Sales Forces Effectiveness, Leading Chains Report),
Ad Hoc reports (questioners of doctors, pharmacists, patients, etc.),
Market access pre-launch and competitive intelligence studies,
Forecasting of total market development,
Targeting services,
Strategic consulting,
Staff training.
MARKET
We blend industry expertise and advanced technology to deliver the most accurate perspectives and in-depth analytics on pharmaceutical dynamics to achieve together with our clients we the following business targets:
launching new products and managing brands successfully,
improving sales effectiveness and upgrading personnel management,
optimizing resources allocation among different regions and countries,
identifying hidden market sectors’ potential and defining the realistic aims based on the opportunities, market share and growth rate.
Sectors we serve include private pharmaceutical sector, government, pharmacies, pharmaceutical distributors.
DEVELOPMENT
We are happy to support you with evidence-based business guidance based on a unique, fully customizable approach in order to meet your business needs!
As the founder of SMD what was it the prompted you to create this company and what were your objectives at that time? Up until 2003 when I created SMD,…
You recently switched from Novartis to Unipharm. Given the major differences in environment and portfolio, what was it about Unipharm in particular that attracted you and what are you bringing…
Since 2006 Teva has been on a solid phase of growth and consolidation, mainly through the acquisitions of IVAX in 2006, Pliva (Barr) in 2008 and ratiopharm in 2010, which…
Following Takeda’s acquisition of Nycomed earlier this year, how has the transaction affected your operations in Ukraine and what synergies were generated by it? Regarding the integration process, we are…
As the founder of SMD what was it the prompted you to create this company and what were your objectives at that time? Up until 2003 when I created SMD,…
If you could provide our readers with your philosophy when you founded Sayenko Kharenko in 2004. What were the market needs that were perhaps missing that you identified and wanted…
It has been one year since you were appointed as the head of UCB’s operations in Ukraine. What was the mission of your assignment when you took this position and…
Considering you only took over as CEO from your father in 2009, what was the mandate that was given to you as new CEO of the company – including your…
Orion’s global strategy focuses on the CIS and Eastern European markets that still exhibit large growth potential and are expanding, despite a reverse trend for the rest of the industry.…
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies…
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Since the establishment of Astellas’ predecessor Brocade in Russia in 1992, what has been Astellas’ evolution in Ukraine? Astellas has been present in Ukraine for 16 years, first as Yamanouchi…
See our Cookie Privacy Policy Here
